New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava.

 

sapien_xt_sapien_3 TAVR devicesThe bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group.

 

301 patients presenting bicuspid aortic valve undergoing transcatheter aortic valve replacement (TAVR) were analyzed. 199 of these patients receive a first generation valve (FG) (Sapien XT: 87 y CoreValve: 112) and 102 a new generation valve (NG) (Sapien 3: 91 y Lotus: 11).

 

Populations were similar, except for ejection fraction, which resulted lower in those receiving NG (52.9% vs. 47.5%; p=0.004).

 

Device success rate was higher in those receiving NG:

NG: 92.2%

FG: 80.9%

[p=0.01]

 

Mild or severe paravalvular leak was also lower with NG:

NG: 0%

FG: 8.5%

[p=0.002]

 

There were no differences in:

  • Stroke
  • Life threatening bleeding
  • Major vascular complications
  • Kidney function deterioration
  • Safety end points
  • Cardiovascular or all-cause mortality in both groups at 30 days and one year (4.3% and 14.1%).

 

At multivariable analyzis, EuroSCORE ≥20, major bleeding and kidney function deterioration was associated to mortality (stages 2 or 3).

 

Conclusion

TAVR evolution in patients with bicuspid valve disease is favorable. New generation devices are associated with less paravalvular leak and higher device success.

 

Editorial Comment

This is the largest series to compare new generation devices against prior devices in this complex scenario to show they are beneficial in terms of device success and absence of paravalvular leak, with no differences in the rest of end points at one year.

 

Surely, at longer follow up, the presence of mild or severe paravalvular leak would translate into death.

 

Original Title: Transcatheter Aortic Valve Replacement with Early-and New-Generation Devices in Bicuspid Aortic valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2016;68:1195-205.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, questions or suggestions here below.

More articles by this author

Hemodynamic Outcomes of Edge-to-Edge Repair in Degenerative and Functional Mitral Regurgitation

Transcatheter edge-to-edge mitral valve repair (M-TEER) has become an established therapeutic option for mitral valve disease. Among the available techniques, M-TEER using the MitraClip...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...

Dual-Prep Registry: Atherectomy and IVL for Severe Coronary Calcification

Severe coronary calcification remains one of the most challenging scenarios in percutaneous coronary intervention (PCI). Although rotational or orbital atherectomy and intravascular lithotripsy (IVL)...

Hemodynamic Outcomes of Edge-to-Edge Repair in Degenerative and Functional Mitral Regurgitation

Transcatheter edge-to-edge mitral valve repair (M-TEER) has become an established therapeutic option for mitral valve disease. Among the available techniques, M-TEER using the MitraClip...